在非小细胞肺癌中,以EHMT2为媒介的转录重编程驱动神经内分泌转化
Cheng Yang1,2, Shuxiang Ma3, Jie Zhang1,2
1Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang 110016, China.
概括
小细胞肺癌 (SCLC) 的转变驱动了对表皮生长因子受体氨酸激酶抑制剂 (TKI) 的耐药性. 抑制EHMT2恢复了TKI的敏感性,为克服肺腺癌中的erlotinib耐药性提供了一种治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 肺腺癌可以转化为小细胞肺癌 (SCLC),这是对表皮生长因子受体氨酸激酶抑制剂 (TKIs) 耐药性的机制.
- 有限的临床样本阻碍了对抗性机制的理解和开发有效疗法的发展.
- 临床前模型对于研究神经内分泌 (NE) 转化中的TKI耐药性至关重要.
研究的目的:
- 为了阐明转录性重编程在NE转化中驱动对erlotinib的抗性.
- 确定关键的分子途径和潜在的治疗点,以克服TKI抵抗.
主要方法:
- 开发临床前的NE转化模型.
- 在NE转变细胞系和异种移植模型中分析基因表达.
- 研究EHMT2和WNT/β-catenin通路在TKI耐药性中的作用.
- 在临床SCLC样本中验证发现.
主要成果:
- 在NE转换中确定了EHMT2和WNT/β-catenin通路基因的增强表达.
- 证明EHMT2介导的SFRP1促进物甲基化激活了WNT/β-catenin通路,导致TKI耐药性.
- 在临床SCLC样本中观察到类似的EHMT2和SFRP1表达变化.
- 表明抑制EHMT2可以恢复erlotinib的敏感性,并延迟耐药性.
结论:
- 涉及EHMT2和WNT/β-catenin的转录重编程机制驱动了ERLOTINIB在NE转化中的耐药性.
- 在肺腺癌中,EHMT2是克服TKI耐药性的潜在治疗标.
- 准EHMT2可能会使瘤对erlotinib重新敏感,并改善治疗结果.
相关概念视频
lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Methods of Nuclear Reprogramming
1.8K
Nuclear reprogramming is a process of transforming one cell type into an unrelated cell type by epigenetic changes that alter the cell’s original gene expression pattern. Such epigenetic changes force cells to express a different set of genes, which play a significant role in inducing transformation into other cell types. Nuclear reprogramming offers applications in reproductive cloning for livestock propagation and regenerative medicine — developing patient-specific cells for...
1.8K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Forced Transdifferentiation
1.9K
Transdifferentiation, also known as lineage reprogramming, was first discovered by Selman and Kafatos in 1974 in silkmoths. They observed that the moths’ cuticle-producing cells transformed into salt-producing cells. Many such cases of natural transdifferentiation occur in organisms. In humans, pancreatic alpha cells can become beta cells. In newts, the loss of the eye’s lens causes the pigmented epithelial cells to transdifferentiate into the lens cells.
Artificial...
Artificial...
1.9K
Non-LTR Retrotransposons
11.5K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.5K


